Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.37 |
| ▸ | TUBB | P07437 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6220756 | 0.78 | MAPT (0.51) | MAPK8MAPK9MAPK10SMN1; SMN2CYP1A2 | |
| SCHEMBL9209481 | 0.78 | ATR (0.50) | MAPK8MAPK9MAPK10PTPN1KDM4E | |
| SCHEMBL3554545 | 0.78 | MAPK8 (0.45) | MAPK8MAPK9MAPK10HPGDSMN1; SMN2 | |
| SCHEMBL3960185 | 0.78 | ALDH1A1 (0.51) | MAPK8MAPK9MAPK10HPGDSMN1; SMN2 | |
| SCHEMBL4066272 | 0.77 | MAPK8 (0.52) | MAPK8MAPK9MAPK10HPGDPTPN1 | |
| SCHEMBL10563795 | 0.76 | KDM4E (0.48) | MAPK8MAPK9MAPK10HPGDSMN1; SMN2 | |
| SCHEMBL10076110 | 0.74 | MAPK10 (0.56) | MAPK8MAPK9MAPK10HPGDSMN1; SMN2 | |
| SCHEMBL3556694 | 0.74 | MAPK8 (0.44) | MAPK8MAPK9MAPK10HPGDSMN1; SMN2 | |
| SCHEMBL8357991 | 0.73 | MAPK10 (0.55) | MAPK8MAPK9MAPK10HPGDPTPN1 | |
| SCHEMBL3563299 | 0.73 | MAPK10 (0.55) | MAPK8MAPK9MAPK10SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732933-B1 | COMPOUNDS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1732933-B1 | COMPOUNDS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| EP-1732933-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097805-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | PCSK9, LIPC, APOB | MAPK8 3628/4885MAPK9 2333/4885MAPK10 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.